Announced today by VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.
What is exposome?
The human body is subjected to and responds to complex exposures throughout the lifespan, including exposures from the environment, diet, lifestyle. For this highly complex interaction, the term exposome was recently coined by Dr. Christopher Wild at the World Health Organization‘s International Agency for Research on Cancer.
The exposome analysis, therefore, complements the human genome by providing a comprehensive description of individuals’ lifelong environmental exposures. Exposome research aims to look at the holistic view of the human body’s exposures, how the body responds to those exposures, and their combined effects.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7751451-vichy-announces-exposome-grant/
Announced today by VICHY Laboratoires, the VICHY EXPOSOME GRANT will promote and encourage research activity on the skin exposome. One research grant of 15 000 € will be awarded annually to a research project proposal in the field of exposome and skin.
What is exposome?
The human body is subjected to and responds to complex exposures throughout the lifespan, including exposures from the environment, diet, lifestyle. For this highly complex interaction, the term exposome was recently coined by Dr. Christopher Wild at the World Health Organization‘s International Agency for Research on Cancer.
The exposome analysis, therefore, complements the human genome by providing a comprehensive description of individuals’ lifelong environmental exposures. Exposome research aims to look at the holistic view of the human body’s exposures, how the body responds to those exposures, and their combined effects.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7751451-vichy-announces-exposome-grant/
The most detailed analysis yet of the role germline mutations in genes associated with cancer predisposition play in the development of childhood cancer suggests that comprehensive genomic screening may be warranted on all pediatric cancer patients, not just those with a family history of cancer. The study from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project appears in the November 19 edition of the New England Journal of Medicine.
Ultimately, researchers anticipate that systematic monitoring of patients and family members who have germline mutations in cancer predisposition genes will allow the detection of cancers at their earliest and most curable stage, thereby improving the outcomes for these children and family members.
To view the multimedia release go to:
http://www.multivu.com/players/English/7692851-st-jude-hospital-genome-project/
Advanced technology has the power to transform healthcare, a world leader in the field of genomicsDr Leroy Hood, has said ahead of the 3rd Astellas Innovation Debate: i-Genes – What the DNA and Data Revolutions mean for our Health, taking place on Thursday 29th January 2015 at the Royal Institution of Great Britain.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7430051-dr-leroy-hood-astellas-debate/
BloodCenter of Wisconsin’s Diagnostic Laboratories today announced the availability of a comprehensive cancer mutation HemeOnc Panel using next generation sequencing (NGS) technology. The NGS panel developed by BloodCenter of Wisconsin is designed to detect variants in 30 genes that are either prognostic or diagnostic for 10 different myeloid hematologic malignancies.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7363151-bloodcenter-of-wisconsin-launches-next-generation-sequencing-hemeonc-panel/
Research led by the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project has identified a fusion gene responsible for almost 30 percent of a rare subtype of childhood leukemia with an extremely poor prognosis.
The finding offers the first evidence of a mistake that gives rise to a significant percentage of acute megakaryoblastic leukemia (AMKL) cases in children. AMKL accounts for about 10 percent of pediatric acute myeloid leukemia (AML). The discovery paves the way for desperately needed treatment advances.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58586-st-jude-children-s-research-hospital-gene-sequencing-childhood-leukemia
Researchers studying the genetic roots of the most common malignant childhood brain tumor have discovered missteps in three of the four subtypes of the cancer that involve genes already targeted for drug development.
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
Researchers have identified the first gene mutation associated with a chronic and often fatal form of neuroblastoma that typically strikes adolescents and young adults. The finding provides the first clue about the genetic basis of the long-recognized but poorly understood link between treatment outcome and age at diagnosis.
The study involved 104 infants, children and young adults with advanced neuroblastoma, a cancer of the sympathetic nervous system. Investigators discovered the ATRX gene was mutated only in patients age 5 and older. The alterations occurred most often in patients age 12 and older. These older patients were also more likely than their younger counterparts to have a chronic form of neuroblastoma and die years after their disease is diagnosed.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52992-st-jude-pediatric-cancer-genome-project-neuroblastoma-research
Science of Tears and Emotion
The Start of Brain Research
So Lydia Cassone said that they all went back to their respective scientists and asked what on earth this had to do with memory. And do you know that since about the late 1960s and early 1970s we have learned more about the mind, more about the subconscious mind, more about the body, more about the mind/body connection than in any previous 2000 years in our history. Look at just what we’ve learned.
Genome and Proteins
Look at the genome stuff that we’ve learned. Do you know that proteins are being investigated. They say that there are 6 million proteins in the body and when we know all the proteins in the body, we will be able to cure anything in humans. It’s frightening isn’t it, but that’s where it’s going. We’ve learned a lot in the last 40 or so years.
Tears – a Different Chemical Composition
One of the things that we’ve learned, I use in seminars and I think it’s really interesting. You know tears that we have. We can have tears of sadness and we can also have tears of happiness. Well do you know that they have a different chemical composition? So in other words we’re doing something different to our body when we have tears of sadness and tears of joy. Now that coupled with another research scientist, Rappaport, is fantastic information.
Emotion is Memory for the Subconscious Mind
You see, Rappaport showed emotion is memory for the subconscious mind. Emotion is memory and this was proved in 1971. What was actually proved was that emotion is not only involved with memory, it is the very basis on which memory takes place.
A Quick Demonstration
Now, when you think about that, a quick demonstration is that you could go back in your mind right now to something that you didn’t like – something that was an adversity, a trauma ….. OK, no need to go any further as you’ve probably got it already. Don’t think about it any more. But you go there easily, you know what the occasion was, you know what hurt – all that sort of thing.
Another Demonstration
And I could also ask you to go back to a really fantastic event in your life. You might for example go back to when you were riding your two-wheeler bike for the first time, or maybe your first kiss, or maybe a fantastic result at sport or in school, or something like that. We have so many good, joyous occasions in our mind and they will come up.
How Did You Remember
Now, how did you remember them? That’s the key – how did you remember them? To remember either the negative event or the joyous event, did you have to tell other people about it? Did you have to write about it again and again? Did you have to make a mind map about it? Did you have to do all those sorts of things to remember it? No, it just stuck fast didn’t it. It’s right there. So, in other words, the emotion of the event made it stay in your memory.
Remembering With Only Positive Emotion
So now, if we can remember with both negative emotion and positive emotion, do we use negative emotion to enhance imprinting on our memory? The answer is no, because of the tear stuff. Tears of sadness, tears of joy – different chemical constitution. We know we’re doing something different to our body with negative stuff and the negative stuff doesn’t make us feel good. So therefore we only use positive, joyous memory connections to enhance memory within the subconscious mind. So that’s something that came out of this science a long time ago.
By Sandy MacGregor – http://www.selfimprovementdeals.com
See it on Video – 08 of 16 Science of Tears and Emotion
Next Video – 09 Sandy's Trauma and Beginning of Grief
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Researchers have discovered that a subtype of leukemia characterized by a poor prognosis is fueled by mutations in pathways distinctly different from a seemingly similar leukemia associated with a much better outcome. The findings from the St. Jude Children’s Research Hospital — Washington University Pediatric Cancer Genome Project (PCGP) highlight a possible new strategy for treating patients with this more aggressive cancer.
The work provides the first details of the genetic alterations fueling a subtype of acute lymphoblastic leukemia (ALL) known as early T-cell precursor ALL (ETP-ALL). The results suggest ETP-ALL has more in common with acute myeloid leukemia (AML) than with other subtypes of ALL. The study appears in the January 12 edition of the journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46768-st-jude-cancer-genome-sequencing-project-combat-aggressive-leukemia
